Inventor · disambiguated record
Matthias Emanuel Liechti
Also filed as: LIECHTI MATTHIAS E · LIECHTI MATTHIAS EMANUEL
6 granted patents·29 pending applications·21 citations·filing 2021–2025
79Inventor score
Top patents by PatentIndex Score
35 records- 0194US11364221B2MDMA treatment to enhance acute emotional effects profile of LSD, psilocybin or other psychedelicsUNIV BASEL·Filed 2021·Granted Jun 21, 2022·9 cites·16 claims
- 0291US11963946B2MDMA treatment to enhance acute emotional effects profile of LSD, psilocybin, or other psychedelicsUNIV BASEL·Filed 2021·Granted Apr 23, 2024·3 cites·4 claims
- 0389US11896670B2Synthesis routes to access MDMA prodrugs by using controlled and non-controlled intermediatesMIND MEDICINE INC·Filed 2022·Granted Feb 13, 2024·2 cites·2 claims
- 0487US11717517B2LSD dose identificationUNIV BASEL·Filed 2021·Granted Aug 8, 2023·4 cites·31 claims
- 0586US11959929B2Method of quantifying lysergic acid diethylamide (LSD) and 2,3-dihydro-3-hydroxy-2-oxo lysergide (O-H-LSD) in human plasmaUNIV BASEL·Filed 2021·Granted Apr 16, 2024·3 cites·5 claims
- 0678US2023227398A1Mescaline derivatives with modified actionMIND MEDICINE INC·Filed 2023·Application pending·0 cites
- 0773US2022267252A1Mescaline derivatives with modified actionMIND MEDICINE INC·Filed 2022·Application pending·0 cites
- 0873US2023201160A1Mdma treatment to enhance acute emotional effects profile of lsd, psilocybin or other psychedelicsUNIV BASEL·Filed 2023·Application pending·0 cites
- 0972US2023285384A1Using geno- or phenotyping to adjust lsd dosingUNIV BASEL·Filed 2023·Application pending·0 cites
- 1072US2022347169A1Using geno- or phenotyping to adjust lsd dosingUNIV BASEL·Filed 2022·Application pending·0 cites
- 1170US2022280501A1Using geno- or phenotyping to adjust lsd dosingUNIV BASEL·Filed 2022·Application pending·0 cites
- 1269US2023355575A1Mdma prodrugs to assist psychotherapyMIND MEDICINE INC·Filed 2023·Application pending·0 cites
- 1368US2024115710A1Synthesis routes to access mdma prodrugs by using controlled and non-controlled intermediatesMIND MEDICINE INC·Filed 2023·Application pending·0 cites
- 1467US2023091369A1Mescaline derivatives with modified actionMIND MEDICINE INC·Filed 2022·Application pending·0 cites
- 1566US2023000799A1Effects of mescaline and of mescaline analogs (scalines) to assist psychotherapyUNIV BASEL·Filed 2022·Application pending·0 cites
- 1665US2025312309A1Allyl-and propargylamine-type phenethylamines and tryptamines for treating medical disordersMIND MEDICINE INC·Filed 2024·Application pending·0 cites
- 1764US2024307345A1R-MDMA and S-MDMA TO ASSIST PSYCHOTHERAPYUNIV BASEL·Filed 2024·Application pending·0 cites
- 1864US2023330085A1Lsd dose identificationUNIV BASEL·Filed 2023·Application pending·0 cites
- 1963US2022151986A1Mdma prodrugs to assist psychotherapyMIND MEDICINE INC·Filed 2021·Application pending·0 cites
- 2063US2024174594A14-alkenyl and 4-alkynyl phenethylamine derivatives and related compounds with modified dom-like actionMIND MEDICINE INC·Filed 2023·Application pending·0 cites
- 2162US2023414583A1Lysergic acid derivatives with modified lsd-like actionMIND MEDICINE INC·Filed 2023·Application pending·0 cites
- 2262US2022265582A1Effects of mescaline and of mescaline analogs (scalines) to assist psychotherapyUNIV BASEL·Filed 2022·Application pending·0 cites
- 2361US2023285327A1Desoxyscaline derivatives with modified mescaline-like actionMIND MEDICINE INC·Filed 2023·Application pending·0 cites
- 2461US2023233688A1Mdma prodrugs to assist psychotherapyMIND MEDICINE INC·Filed 2023·Application pending·0 cites
- 2560US2023150906A1Desoxyscaline derivatives with modified mescaline-like actionMIND MEDICINE INC·Filed 2022·Application pending·0 cites
- 2660US2023218568A1R-MDMA and S-MDMA TO ASSIST PSYCHOTHERAPYUNIV BASEL·Filed 2022·Application pending·0 cites
- 2756US2022273628A1Effects of lysergic acid diethylamide (lsd) and of lsd analogs to assist psychotherapy for generalized anxiety disorder or other anxiety not related to life-threatening illnessUNIV BASEL·Filed 2022·Application pending·0 cites
- 2856US2022323405A1Combination product using 3,4-methylenedioxymethamphetamine and carvedilol for the treatment of psychiatric disordersUNIV BASEL·Filed 2022·Application pending·0 cites
- 2955US2021386704A1Mdma response predictionUNIV BASEL·Filed 2021·Application pending·0 cites
- 3054US2022040150A1Intravenous dmt administration method for dmt-assisted psychotherapyUNIV BASEL·Filed 2021·Application pending·0 cites
- 3150US11801256B2Antidepressant-psilocybin co-treatment to assist psychotherapyUNIV BASEL·Filed 2022·Granted Oct 31, 2023·0 cites·8 claims
- 3250US2021267977A1Controlling effects after 5ht2a agonists administrationUNIV BASEL·Filed 2021·Application pending·0 cites
- 3350US2025152565A1Effects of lysergic acid diethylamide (lsd) and of lsd analogs to assist psychotherapy for generalized anxiety disorder or other anxiety not related to life-threatening illnessUNIV BASEL·Filed 2025·Application pending·0 cites
- 3449US2023039395A1Lsd and psilocybin dose equivalence determinationUNIV BASEL·Filed 2022·Application pending·0 cites
- 3546US2022082578A1Method of quantifying psilocybin's main metabolites, psilocin and 4-hydroxyindole-3-acetic acid, in human plasmaUNIV BASEL·Filed 2021·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →